Endonuclease News and Research

RSS

SARS-CoV-2's microRNAs may have promoted its jump to humans

A new study uses machine learning to explore the small microRNAs (or miRNAs) of SARS-CoV-2 that may determine the virus's ability to successfully infect humans by altering the course of transcriptional events.

1 Dec 2020

New research on small non-coding RNAs and SARS-CoV-2

A recently published mini-review in the Frontiers in Microbiology on the altered expression of small non-coding RNAs during coronavirus-mediated infections.

26 Oct 2020

Inhaled steroid ciclesonide suppresses SARS-CoV-2 replication in vitro

A new paper by researchers at Japan’s National Institute of Infectious Diseases and published on the preprint server bioRxiv in August 2020 reports the in vitro suppression of coronavirus (CoV) replication by an inhaled corticosteroid (ICS) ciclesonide.

26 Aug 2020

Exploiting 'synthetic lethality' to identify cancer targets

With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of "synthetic lethality," exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the survival of cancer cells.

28 Jul 2020

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows

Horizon Discovery Group plc, today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout.

8 Jul 2020

Wyss Institute and Cytosurge collaborate to improve CRISPR multiplexing

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cytosurge AG, a company manufacturing unique high-precision nanotechnology instruments, announced that they will collaboratively investigate CRISPR-based approaches to more effectively introduce multiple edits into the genome of single cells, while minimizing CRISPR-related toxicity.

4 May 2020

Reactivating ‘tumor suppressor’ genes could offer new therapeutic approach for cancer

Scientists have developed a method which is able to switch ‘tumor suppressor’ genes back on after they have been silenced by cancer cells.

25 Sep 2019

Scientists develop method to reactivate tumor suppressor genes 'silenced' by cancer

Scientists at UCL have developed a method to reactivate 'tumor suppressor' genes, which are switched off by cancer cells - a finding which could lead to new targeted biotherapies for cancer.

23 Sep 2019

How cell-free DNA can be targeted to prevent spread of tumors

Cell-free DNA (cfDNA) is DNA found in trace amounts in blood, which has escaped degradation by enzymes.

12 Jul 2019

New study could fine-tune the CRISPR gene editing process

The introduction of the tool for gene editing, the so-called gene scissors CRISPR, in 2007 was a revolution within medical science and cell biology.

30 Nov 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

DermTech completes enrollment in clinical study to assess DNA damage and reversal

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today it has completed enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of topical agents T4 endonuclease and photolyase to reduce DNA damage induced as measured through gene expression analysis.

19 Sep 2018

Single dose of influenza drug can shorten duration of illness, study reveals

A single dose of a new influenza drug can significantly shorten the duration of the illness in teens and adults, according to a study published in the prestigious New England Journal of Medicine.

6 Sep 2018

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

23 Aug 2018

Researchers examine new influenza drug's mode of action in detail

The new influenza drug Xofluza, developed by the Japanese pharmaceutical company Shionogi, was approved for clinical use in Japan in February 2018.

26 Jun 2018

Gene editing tool used to detect cancer

Researchers have developed a DNA detection system that can detect the presence of bacterial and viral DNA, which could be a valuable diagnostic tool for a range of disorders.

16 Feb 2018

Scientists identify special pair of RNA scissors with many functions

CRISPR/Cas systems are known as promising "gene scissors" in the genome editing of plants, animals, and microorganisms by targeting specific regions in their DNA - and perhaps they can even be used to correct genetic defects.

8 Feb 2018

Cellectis wins European patent for CRISPR use in T-cells

Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.

24 Jul 2017

Researchers discover how new molecular scissors unzip and cleave DNA with high accuracy

Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.

6 Jul 2017